Improving the outcome of patients with toxic epidermal necrolysis and Stevens-Johnson syndrome.
- 1 March 2000
- journal article
- editorial
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 136 (3) , 410-411
- https://doi.org/10.1001/archderm.136.3.410
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Inhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous ImmunoglobulinScience, 1998
- Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal NecrolysisNew England Journal of Medicine, 1995
- Analysis of the Acute Ophthalmic Manifestations of the Erythema Multiforme/Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Disease SpectrumPublished by Elsevier ,1995
- The Outcome of Stevens-Johnson Syndrome Treated with CorticosteroidsAllergy and Asthma Proceedings, 1995
- Severe Adverse Cutaneous Reactions to DrugsNew England Journal of Medicine, 1994
- Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patientsArchives of Dermatology, 1987
- Severe Cutaneous Reactions among American Travelers Using Pyrimethamine-Sulfadoxine (Fansidar®) for Malaria ProphylaxisThe American Journal of Tropical Medicine and Hygiene, 1986
- Burn Unit Management of Toxic Epidermal NecrolysisArchives of Surgery, 1978